RDS is a medtech company focused on remote patient monitoring. Its flagship product, MultiSense, is a patented telemonitoring system that the company develops, manufactures and markets. The company collaborates with international research initiatives such as DARE and 5G-OR and has been incubated at SEMIA/Quest for Health while being accelerated by PariSanté Campus. Emphasizing an eco-conscious approach, RDS aims to set new standards for telemonitoring across Europe. With its latest funding, the firm plans to expand commercialization in France, Germany and the broader European market and to conduct additional clinical trials to support reimbursement applications. The team is simultaneously preparing for FDA registration with the goal of entering the U.S. market in 2028. Elie Lobel leads the company as CEO, and no revenue or user metrics have been disclosed.

Total raised

$36M

Funding rounds

5

Latest round

Series A

Latest activity

Sep 2025